Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

Company Overview

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a specialty pharmaceutical company focused on developing and commercializing products for underserved areas of healthcare. The company has historically concentrated on anti-infective therapies, oncology treatments and supportive-care products, with an emphasis on therapies that address significant unmet medical needs.

Citius’ lead programs have included Mino-Lok, an investigational antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while preserving the catheter. The company has also developed LYMPHIR (denileukin diftitox-cxdl), an oncology therapy for adults with relapsed or refractory cutaneous T-cell lymphoma. LYMPHIR received approval from the U.S. Food and Drug Administration in 2024 and is being advanced through the company’s oncology operations.

The company’s activities have primarily focused on the U.S. market and on obtaining regulatory approval and commercializing specialty therapies. Citius Pharmaceuticals was founded in 2010 and is headquartered in New Jersey. Its leadership has included Myron Holubiak as chief executive officer and Leonard Mazur as chairman, although management roles may change over time.

Key Stats

• Today's Range: $0.58 to $0.60
• 50-Day Range: $0.48 to $0.78
• 52-Week Range: $0.47 to $2.19
• Volume: 279,888 shs
• Average Volume: 359,276 shs
• Market Capitalization: $16.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

Citius Pharmaceuticals Stock Analysis - MarketRank™

Citius Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 670th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Citius Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Citius Pharmaceuticals has a consensus price target of $5.00, representing about 733.3% upside from its current price of $0.60.

Amount of Analyst Coverage

Citius Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Citius Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Citius Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Citius Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.59% of the float of Citius Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Citius Pharmaceuticals has a short interest ratio ("days to cover") of 6.06.

Change versus previous month

Short interest in Citius Pharmaceuticals has recently increased by 4.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Citius Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Citius Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Citius Pharmaceuticals this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 5 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.99% of the stock of Citius Pharmaceuticals is held by insiders.

Percentage Held by Institutions

16.88% of the stock of Citius Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/20/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CTXR
• CIK: 1506251
• Web: www.citiuspharma.com
• Phone: (908) 967-6677
• Fax: N/A
• Employees: 20
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Citius Pharmaceuticals: $5.00
• High Price Target: $6.00
• Low Price Target: $4.00
• Potential Upside/Downside: +733.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.43 million
• Net Margins: N/A
• Pretax Margin: -816.00%
• Return on Equity: -59.57%
• Return on Assets: -34.47%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 0.84
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.29 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 27,450,000
• Free Float: 26,083,000
• Market Cap: $16.47 million
• Optionable: Optionable
• Beta: 1.00